Efficacy Evaluation of Dai Dai Flower on Body Weight

NCT ID: NCT04692792

Last Updated: 2021-08-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-01-04

Study Completion Date

2021-06-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess the Dai Dai flower extract on body weight control

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastroenterology

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo drink

Group Type PLACEBO_COMPARATOR

Placebo drink

Intervention Type DIETARY_SUPPLEMENT

consume 1 bottle (50 mL) per day for 8 weeks

Dai Dai flower drink

Group Type EXPERIMENTAL

Dai Dai flower drink

Intervention Type DIETARY_SUPPLEMENT

consume 1 bottle (50 mL) per day for 8 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo drink

consume 1 bottle (50 mL) per day for 8 weeks

Intervention Type DIETARY_SUPPLEMENT

Dai Dai flower drink

consume 1 bottle (50 mL) per day for 8 weeks

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy male or female aged between 20 and 60 years old
* Body mass index (BMI) ≥ 24 (kg/m\^2) or body fat mass ≥ 25%

Exclusion Criteria

* Pregnant or breastfeeding woman
* Implementation in weight loss programs, consumption drugs or supplements for weight control before 3 months of this study
* Participate weight control or fat loss human studies before 3 months of this study
* History of cardiovascular disease, liver disease, kidney disease, endocrine disease, or other major organic diseases (according to subjects reporting).
* Person who has received major surgery or bariatric surgery (according to medical history).
* Person who has received constant drug use.
* People with mental illness
Minimum Eligible Age

20 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

TCI Co., Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hsiu-Mei Chiang, Prof.

Role: PRINCIPAL_INVESTIGATOR

China Medical University, China

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

China Medical University

Taichung, , Taiwan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Taiwan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CMUH109-REC1-161

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.